CD274 and cervical carcinoma: SHR-1701 also showed encouraging antitumor activity and controllable safety in patients with pretreated advanced cervical cancer (NCT03774979) (106), pretreated recurrent/refractory (r/r) gastric cancer (NCT03710265) (107), and treatment-naive PD-L1 positive advanced/metastatic NSCLC (NCT03774979) (108).